Patients must have resolved any serious infectious complications related to therapy
Active infectious disease considered by the Investigator to be incompatible with the protocol.
Patients with an active infectious disease requiring deferral of conditioning; as recommended by an infectious disease specialist
DONOR: With active infectious hepatitis
Baseline chest x-ray with no evidence of active infectious disease or pneumonitis
Patients with evidence of active, non-infectious pneumonia
New or progressive pulmonary infiltrates concerning for new or uncontrolled infectious process
Use of any vaccines against infectious diseases (e.g. varicella, influenza, etc.) up to  weeks ( days) before receiving nivolumab
Use of any vaccines against infectious diseases (e.g. varicella, influenza, etc.) up to  weeks ( days) before receiving nivolumab
Patients must not have any active infectious process.
If recent mold infection (e.g. aspergillus) must have minimum of  days of therapy and responsive disease and be cleared by infectious disease
Patients who have active infectious hepatitis
Any active infection or infectious illness unless fully recovered prior to dosing.
Presence of leukemic or infectious pulmonary parenchymal disease
PART : Active or recent (prior  month) invasive fungal infection without infectious disease (ID) consult and approval
No clinical evidence of uncontrolled active infectious process
(ELIGIBILITY CRITERIA AT TIME OF INFUSION OF GENETICALLY MODIFIED AUTOLOGOUS T CELLS): No clinical evidence of uncontrolled active infectious process
No clinical evidence of uncontrolled active infectious process
Infectious diseases: no clinical evidence of uncontrolled active infectious process
Infectious diseases criteria: no clinical evidence of uncontrolled active infectious process
DONOR: Infectious disease testing will be done per Hemacare policy and AAAB guidelines
DONOR: Active infectious hepatitis
Patients with any infectious process that, in the opinion of the investigator, could worsen or its outcome be affected as a result of the investigational therapy
If recent mold infection, e.g., Aspergillus, must be cleared by infectious disease to proceed
Active or recent (prior  month) invasive fungal infection without infectious diseases (ID) consult and approval
If recent mold infection, e.g., Aspergillus, must be cleared by infectious disease
Active or recent (prior  month) invasive fungal infection without infectious disease (ID) consult and approval
If recent mold infection e.g. Aspergillus - must have minimum of  days of appropriate treatment before bone marrow transplant (BMT) and infection controlled and be cleared by Infectious Disease
Presence of active infectious oral disease excluding oral candidiasis
Presence of active infectious disease excluding oral candidiasis
Patients must not have any active infectious process.
Patients who test positive for infectious hepatitis types A, B, or C within  days of registration are NOT eligible for participation
Infectious disease testing will be done per Hemacare policy and AAAB guidelines
Patients must have resolved any serious infectious complications related to consolidation cycle 
If recent mold infection (e.g. aspergillus) must have minimum of  days of therapy and responsive disease and be cleared by infectious disease
With active infectious disease requiring deferral of conditioning, as recommended by an infectious disease specialist
DONOR: Individuals with active infectious hepatitis
Due to the possible effect of treatment with ipilimumab on the immunologic response to infectious disease vaccines, patients must not have had any infectious disease vaccination (e.g, standard influenza, HN influenza, pneumococcal, meningococcal, tetanus toxoid) within  weeks prior to randomization
Has an active infectious process
Current active infectious disease
Have clinical evidence of concomitant infectious conditions.
All HIV+ patients will be under the care of an infectious diseases specialist; if a relationship with an infectious diseases specialist is not established, infectious disease specialist will be consulted; records of all viral counts and peripheral T-cell counts must be sent to the study coordinator in order to follow these values over the course of treatment
No clinical evidence of uncontrolled active infectious process
Active or recent (prior  month) invasive fungal infection without infectious disease (ID) consult and approval
If recent mold infection (e.g. Aspergillus) must have minimum of  days of therapy and responsive disease and be cleared by infectious disease
Infectious process, which, in the opinion of the investigator, could worsen or its outcome be affected, as a result of the investigational therapy
Active infectious disease concerns
Laboratory or clinical evidence of active infectious hepatitis
Patients with an active infectious disease
Has an active infectious process
Active uncontrolled infection or severe infectious disease
Active uncontrolled infection or severe infectious disease
Active uncontrolled infectious diseases requiring treatment
Known positive for Human Immunovirus (HIV) or infectious Hepatitis type C or active infectious Hepatitis type B.
Any serious concomitant illness or infectious disease requiring treatment, or infectious disease not requiring treatment, but with significant risks for myelosuppressive complications associated with chemotherapy.
Any infectious disease requiring treatment at the time of enrolment or within the previous  weeks.
Serious active infectious disease
Active inflammatory or infectious conditions in either eye or history of idiopathic or autoimmune-associated uveitis
Active infectious disease considered by the Investigator to be incompatible with the protocol.
Active infectious disease excluding oral candidiasis
Known positive for infectious hepatitis type C or active infectious hepatitis type B
Has active infectious disease undergoing systemic treatment excluding oral candidiasis
Active infectious disease excluding oral candidiasis
Patients with ongoing febrile illness or documented infectious disease
Active, uncontrolled infection or severe infectious disease.
Current active infectious disease.
